The role of matrix metalloproteinases in acute coronary syndromes

被引:31
作者
Dabek, Jozefa [1 ]
Kulach, Andrzej [1 ]
Gasior, Zbigniew [1 ]
机构
[1] Med Univ Silesia, Dept Cardiol, PL-40635 Katowice, Poland
关键词
acute coronary syndrome; myocardial infarction; matrix metal loproteinases; MMP;
D O I
10.1016/j.ejim.2007.01.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Matrix metalloproteinases (MMPs) are an expanding group of proteolytic enzymes that participate in numerous physiological and pathological processes including embryogenesis, connective tissue turn-over, healing, angiogenesis, etc. Disturbances in matrixin activity are observed in carcinogenesis, some degenerative processes, and in inflammation, including atherogenesis. The role of matrixins in the pathology of the cardiovascular system seems to be particularly important in two processes: (1) atherosclerotic plaque development and rupture (leading to an acute coronary event) and (2) post-infarction remodeling of myocardium, leading to heart failure. The purpose of this paper is to gather and summarize information about the role of MMPs in acute coronary syndromes (ACS), in both the processes leading to coronary artery occlusion and the "myocardial consequence" of this event. In addition, some benefits and disadvantages of pharmacological intervention into this enzymatic network will be addressed. (C) 2007 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:463 / 466
页数:4
相关论文
共 34 条
[1]  
Aoudjit F, 1998, J IMMUNOL, V160, P2967
[2]   Induction of macrophage elastase (MMP-12) gene expression by statins [J].
Arikan, MC ;
Shapiro, SD ;
Mariani, TJ .
JOURNAL OF CELLULAR PHYSIOLOGY, 2005, 204 (01) :139-145
[3]   Metalloproteinase inhibitors: biological actions and therapeutic opportunities [J].
Baker, AH ;
Edwards, DR ;
Murphy, G .
JOURNAL OF CELL SCIENCE, 2002, 115 (19) :3719-3727
[4]  
BARRETT AJ, 2004, HDB PROTEOLYTIC ENZY
[5]   MMP inhibitors: experimental and clinical studies [J].
Belotti, D ;
Paganoni, P ;
Giavazzi, R .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1999, 14 (04) :232-238
[6]  
COKER MS, 1997, CIRCULATION S1, V96, P689
[7]  
Danielsen CC, 1998, J MOL CELL CARDIOL, V30, P1431
[8]   The next generation of MMP inhibitors - Design and synthesis [J].
De, B ;
Natchus, MG ;
Cheng, MY ;
Pikul, S ;
Almstead, NG ;
Taiwo, YO ;
Snider, CE ;
Chen, LY ;
Barnett, B ;
Gu, F ;
Dowty, M .
INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 :40-60
[9]   Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction [J].
Ducharme, A ;
Frantz, S ;
Aikawa, M ;
Rabkin, E ;
Lindsey, M ;
Rohde, LE ;
Schoen, FJ ;
Kelly, RA ;
Werb, Z ;
Libby, P ;
Lee, RT .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (01) :55-62
[10]   Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2 and -3 in rabbit aortic smooth muscle cells [J].
Fabunmi, RP ;
Baker, AH ;
Murray, EJ ;
Booth, RFG ;
Newby, AC .
BIOCHEMICAL JOURNAL, 1996, 315 :335-342